

Comparison of Factors Which Induce Differentiation of the Murine Myeloid Leukaemic Cell Line M1 *

D.P. Gearing

A. Introduction

Naturally occurring regulatory molecules which can cause the terminal differentiation of leukaemic cells have recently been the subject of great interest, and to date, several protein factors have been described that can induce the differentiation of various myeloid leukaemic cells *in vitro*. The haematopoietic colony-stimulating factors, granulocyte-CSF (G-CSF) and granulocyte/macrophage-CSF (GM-CSF) [1, 2], which act as both proliferative and differentiative stimuli for normal myeloid progenitors, are able to induce the differentiation of certain murine and human myeloid leukaemic cells (including murine WEHI-3BD⁺ and M1 and human HL-60) [3–5]. By contrast, a number of other activities have been described which are capable of inducing the differentiation of murine M1 leukaemic cells, yet which do not stimulate the proliferation of normal progenitor cells [6–8]. With the recent cloning of myeloid leukaemia inhibitory factor (LIF [22]; =D-factor [6]), they have all been cloned. In this report the genetic and polypeptide structures of LIF are compared with those of two growth factors also known to cause differentiation of M1 cells: G-CSF and interleukin-6 (IL-6; MGI-2).

The Walter and Eliza Hall Institute of Medical Research, Post Office, Royal Melbourne Hospital, Victoria, 3050, Australia

* This work was supported by the Anti-Cancer Council of Victoria, the National Health and Medical Research Council (Canberra), the AMRAD Corporation Ltd. (Melbourne) and the National Institutes of Health, Bethesda, MD, USA, Grant no. CA22556.

B. Genetic and Polypeptide Structures of M1 Differentiation-inducing Factors

I. G-CSF

Natural and recombinant G-CSF can induce the terminal differentiation of M1 leukaemic cells [9]. Genomic and cDNA sequences for both human and murine G-CSF have been reported [10, 11]. The genes are highly homologous and the encoded proteins display 76% identity with three insertions or deletions [11]. Murine G-CSF consists of 178 amino acids with a calculated Mr of 19061 and is O-glycosylated to an Mr of approximately 24000–25000. Comparison of the structures of human G-CSF cDNAs and the chromosomal gene revealed that there is a possibility of two different G-CSF molecules consisting of 177 or 174 amino acids [10], corresponding to a calculated molecular mass of 18671 for the smaller version. Native human G-CSF is O-glycosylated to approximately 21000 daltons [12]. Neither human nor murine G-CSF have any N-linked glycosylation sites, and each molecule is presumed to be intramolecularly linked via two disulphide bonds [11].

II. IL-6 [MGI-2]

Over the past few years, IL-6 has been variously known as B-cell stimulatory factor [13], interferon- β 2 [14], 26-kD inducible protein [15], hybridoma/plasmacytoma growth factor [16] and interleukin-HP1 [17]. IL-6 also stimulates the differentiation of B cells [13] and has some activities as a GM-colony-stimulating factor [18]. To this variety of seemingly unrelated activities (and more; see [19])

can be added its ability to cause the terminal differentiation of M1 leukaemic cells (D. Metcalf, personal communication).

Human and murine IL-6 have been cloned [13–15, 20] and show low sequence conservation (42% between proteins, with five insertions or deletions [20]), especially in the amino terminal half. Human IL-6 consists of a 184-amino acid peptide of calculated mass 20 781 which is presumed to be glycosylated to its observed native Mr of 26 000 via two potential N-linked and four potential O-linked glycosylation sites [13]. Murine IL-6 consists of 187 residues with a calculated Mr of 21 710 which is variably O-glycosylated to between 22 000 and 29 000 daltons [20, 21].

The primary sequence of the IL-6 protein revealed significant homologies with the sequence of G-CSF [13], including the conservation of four cysteine residues. Comparison of their gene sequences suggested that the two genes may be derived from a common ancestral gene [13]. Recently, it has been demonstrated that the sequence of at least one form of purified MGI-2 [7] is the same as that of murine IL-6 (A. Zilberstein and L. Sachs, personal communication).

III. LIF [D-Factor]

LIF, a factor that we have recently purified [8] and cloned [25, 26] is able to induce the differentiation of M1 cells but, unlike G-CSF, not WEHI-3BD⁺ cells [8]. LIF is of particular interest for leukaemia therapy, because, unlike the CSFs and IL-6, it does not appear to be a proliferative stimulus for either normal or leukaemic progenitor cells [8]. In addition, LIF is unique in that at high concentrations it inhibits M1 colony formation [8]. LIF is one of the most highly conserved of the regulators known to act within the myeloid system. The mature murine and human protein sequences share 78% identity (with no insertions or deletions) [23], and consist of 179 amino

acids. Murine LIF is heavily glycosylated from its calculated protein mass of ~20 000 daltons to approximately 58 000 daltons, via mostly potential N-linked and some potential O-linked glycosylation sites [22]. The murine and human LIF molecules share six conserved cysteine residues. D-factor [6] has recently been purified and its determined amino acid sequence is the same as that of murine LIF (M. Hozumi, personal communication).

C. Is LIF Related to G-CSF and IL-6?

Given that G-CSF and IL-6 appear to be related in both polypeptide and gene arrangements [13, 24], it is interesting to consider whether LIF has any relationship to these two regulators.

I. Protein Sequence/Structure

LIF shares little detectable homology with G-CSF and IL-6 when their protein sequences are compared. Furthermore, the number and positions of the cysteine residues in the LIF proteins are not equivalent to those of G-CSF and IL-6 (Fig. 1), and whilst G-CSF and IL-6 are minimally glycosylated (mostly O-linked) [11–13, 20], LIF is heavily N-glycosylated [8, 22, 23]. However, murine and human LIF share two small patches of homology with murine and human G-CSF and minor similarities may be observed in the distribution of proline clusters in all three molecules, and each is of a similar length. Thus, at the polypeptide level LIF bears only little resemblance to G-CSF and even less to IL-6.

II. Gene Organization

Comparison of the gene organization of LIF with that shared by G-CSF and IL-6 reveals little similarity (Fig. 2). The LIF genes comprise three exons compared with the five exons of both G-CSF and IL-6 and, apart from the coding region of the first exon of murine LIF, which is the




Fig. 1. Comparison of LIF, G-CSF and IL-6 polypeptides. Proline residues are marked by vertical bars and cysteine residues as *c*. Regions of homology are indicated by shaded boxes. (Based on reports in [10, 11, 13, 20, 22, 23])




Fig. 2. Comparison of the gene organization between IL-6, G-CSF and LIF. Boxes represent exons. The coding and noncoding regions are shown by closed and open boxes, respectively. The numbers above and below the boxes indicate the numbers of amino acids of exons and those of nucleotides of exons for coding region, respectively. The numbers below the lines show the length of introns. (After the scheme presented in [24] and the data of [10] and [23]. Murine LIF gene organization: Gearing, King and Gough, Unpublished work)

same length as that of human IL-6 (6.3 codons), the lengths of the other exons are dissimilar. These data indicate that there is no reason to suggest that the three genes are related. However, it is interesting to note that the sum of the codons in the last three exons of the human G-CSF and IL-6 genes (139 and 142 codons, respectively) is approximately the same as the number of codons in the last exon of the LIF genes (136 codons). This suggests that if these genes are ancestrally related, then the LIF gene could have arisen by exon fusion of three exons into one, or that the G-CSF and IL-6 genes could have been derived by two introns inserting into a common larger last exon.

With the reasonable assumption that IL-6 is the molecule detected earlier as a plasmacytoma growth factor [25, 26], IL-6, G-CSF and LIF share two features in common: (a) when mice are injected with endotoxin, levels of each factor rise sharply in the serum within 1–3 h, and (b) all three molecules are produced *in vitro* by macrophages after priming with endotoxin [25–28] (D. Metcalf, personal communication), and G-CSF and LIF mRNAs are induced in macrophage lines following stimulation with endotoxin (N. Gough, personal communication). This suggests some intended biological coordination in their actions *in vivo* and raises the possibility of common transcriptional activation pathways.

D. Conclusions

From its primary protein sequences and its genetic organization, it can be concluded that LIF is a new structural entity which is probably not related to either G-CSF or IL-6, although the three molecules might in some ways be functionally related. At present, LIF appears unique in that it is not apparently a proliferative stimulus for either normal or leukaemic progenitor cells and it specifically inhibits colony formation and causes terminal differentiation of M1 leukaemic

cells, this contrasts with G-CSF and IL-6, which can provide both a differentiative stimulus to M1 cells and a proliferative stimulus to normal cells.

Acknowledgements. Thanks to Nick Gough, Nic Nicola and Don Metcalf for their useful comments on this manuscript and to Iras Collins for typing.

Note added in proof:

Since this manuscript was submitted, LIF has been shown to be able to suppress the human leukemic cell lines HL60 and U937 when used in combination with GM-CSF or G-CSF [29]. Somewhat surprisingly, and by contrast to its differentiation-inducing activity on M1 leukaemic cells, LIF also has a powerful differentiation-inhibiting activity on embryonic stem [ES] cells [30, 31] and its use will aid in their propagation *in vitro*. In a further twist, COS cell conditioned-media containing LIF can also apparently act as a growth stimulus for the murine haemopoietic cell line DA-1a [32] so its postulated role as a differentiation-only factor may have to be reconsidered.

References

1. Metcalf D (1985) The granulocyte-macrophage colony-stimulating factors. *Science* 229:16–22
2. Metcalf D (1986) The molecular biology and functions of the GM-CSFS. *Blood* 67:257–267
3. Begley CG, Metcalf D, Nicola NA (1987) Purified colony stimulating factors (G-CSF and GM-CSF) induce differentiation in human HL60 leukemic cells with suppression of clonogenicity. *Int J Cancer* 39:99–105
4. Metcalf D, Nicola NA (1982) Autoinduction of differentiation in WEHI-3B leukemia cells. *Int J Cancer* 30:773–780
5. Metcalf D (1979) Clonal analysis of the action of GM-CSF on the proliferation and differentiation of myelomonocytic leukemic cells. *Int J Cancer* 24:616–623

6. Tomida M, Yamamoto-Yamaguchi Y, Hozumi M (1984) Purification of a factor inducing differentiation of mouse myeloid leukemic M1 cells from conditioned medium of mouse fibroblast L929 cells. *J Biol Chem* 259:10978–10982
7. Lipton JH, Sachs L (1981) Characterization of macrophage- and granulocyte-inducing proteins for normal and leukemic myeloid cells produced by the Krebs ascites tumor. *Biochim Biophys Acta* 673:552–569
8. Hilton DJ, Nicola NA, Metcalf D (1988) Purification of a murine leukemia inhibitory factor from Krebs ascites cells. *Anal Biochem* 173:359–367
9. Tomida M, Yamamoto-Yamaguchi Y, Hozumi J et al. (1986) Induction by recombinant human granulocyte colony-stimulating factor of differentiation of mouse myeloid leukemic M1 cells. *FEBS Lett* 207:271–275
10. Nagata S, Tsuchiya M, Asano S et al. (1986) The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. *EMBO J* 5:575–581
11. Tsuchiya M, Asano S, Kaziro Y, Nagata S (1986) Isolation and characterization of the cDNA for murine granulocyte colony-stimulating factor. *Proc Natl Acad Sci USA* 83:7633–7637
12. Nomura H, Imazeki I, Oheda M et al. (1986) Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). *EMBO J* 5:871–876
13. Hirano T, Yasukawa K, Harada H et al. (1987) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. *Nature* 324:73–76
14. Zilberstein A, Ruggieri R, Kora JH, Revel M (1986) Structure and expression of cDNA and genes for human interferon β -2, a distinct species inducible by growth-stimulatory cytokines. *EMBO J* 5:2529–2537
15. Content J, DeWit L, Pierard D et al. (1982) Secretory proteins induced in human fibroblasts under conditions used for the production of interferon β . *Proc Natl Acad Sci USA* 79:2768–2772
16. Van Damme J, Opdenakker G, Simpson RJ et al. (1987) Identification of the human 26-kD protein, interferon β 2 (IFN- β 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. *J Exp Med* 165:914–919
17. Van Snick J, Cayphas S, Vink A et al. (1986) Purification and NH₂-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. *Proc Natl Acad Sci USA* 83:9679
18. Wong GG, Witek-Giannotti JS, Temple PA et al. (1988) Stimulation of murine hemopoietic colony formation by human IL-6. *J Immunol* (1988) 140:3040–3044. *J Immunol* [in press]
19. Wong GG, Clark SC (1988) Multiple actions of interleukin 6 within a cytokine network. *Immunol Today* 9:137–139
20. Van Snick J, Cayphas S, Szikora J-P et al. (1988) cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. *Eur J Immunol* 18:193–197
21. Van Snick J, Vink A, Cayphas S, Uyttenhove C (1987) Interleukin HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. *J Exp Med* 165:641
22. Gearing DP, Gough NM, King JA et al. (1987) Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). *EMBO J* 6:3995–4002
23. Gough NM, Gearing DP, King JA et al. (1988) Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia-inhibitory factor. *Proc Natl Acad Sci USA* 85:2623–2627
24. Yasukawa K, Hirano T, Watanabe Y et al. (1987) Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. *EMBO J* 6:2939–2945
25. Metcalf D (1973) Colony formation in agar by murine plasmacytoma cells: potentiation by hemopoietic cells and serum. *J Cell Physiol* 81:397–410
26. Metcalf D (1974) The serum factor stimulating colony formation in vitro by murine plasmacytoma cells: response to antigens and mineral oil. *J Immunol* 113:235–243
27. Burgess AW, Metcalf D (1980) Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells. *Int J Cancer* 26:647–654
28. Metcalf D, Nicola NA (1985) Synthesis by mouse peritoneal cells of G-CSF, the differentiation inducer for myeloid leukemia cells: stimulation by endotoxin, M-CSF and multi-CSF. *Leukaemia Res* 9:35–50

29. Maekawa T, Metcalf D (1989) Clonal suppression of HL60 and U937 cells by recombinant human leukemia inhibitory factor in combination with GM-CSF or G-CSF. *Leukemia*, in press
30. Williams RL, Hilton DJ, Pease S et al. (1988) Myeloid leukaemia inhibitory factor (LIF) maintains the developmental potential of embryonic stem cells. *Nature* 336:684–687
31. Smith AG, Heath JK, Donaldson DD et al. (1988) Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. *Nature* 336:688–690
32. Moreau J-F, Donaldson DD, Bennett F et al. (1988) Leukaemia-inhibitory factor is identical to the myeloid growth factor, human interleukin for DA cells. *Nature* 336:690–692